UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Heterodimeric JAK―STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

Nature (London), 2012-09, Vol.489 (7414), p.155-159

2012

Link zum Volltext

Verfügbarkeit prüfen

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition

Nature medicine, 2015-12, Vol.21 (12), p.1473-1480

2015

Link zum Volltext

Verfügbarkeit prüfen

JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation

Cancer cell, 2011-02, Vol.19 (2), p.283-294

2011

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms

International journal of hematology, 2013-06, Vol.97 (6), p.695-702

2013

Link zum Volltext

Verfügbarkeit prüfen

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Blood, 2014-03, Vol.123 (13), p.2075-2083

2014

Link zum Volltext

Verfügbarkeit prüfen

Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

Molecular cancer therapeutics, 2020-09, Vol.19 (9), p.1875-1888

2020

Link zum Volltext

Verfügbarkeit prüfen

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

The Journal of clinical investigation, 2010-10, Vol.120 (10), p.3578-3593

2010

Link zum Volltext

Verfügbarkeit prüfen

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent

Cancer discovery, 2012-06, Vol.2 (6), p.512-523

2012

Link zum Volltext

Verfügbarkeit prüfen

Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma

Clinical cancer research, 2008-07, Vol.14 (13), p.4284-4291

2008

Link zum Volltext

Verfügbarkeit prüfen

Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting

Clinical cancer research, 2008-12, Vol.14 (23), p.7682-7690

2008

Link zum Volltext

Verfügbarkeit prüfen

Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1

Molecular pharmacology, 2007-05, Vol.71 (5), p.1435-1443

2007

Link zum Volltext

Verfügbarkeit prüfen

Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1235-1242

2009

Link zum Volltext

Verfügbarkeit prüfen

STATe-of-the-art approach: using oligonucleotide decoys to target the "undruggable"

Cancer discovery, 2012-08, Vol.2 (8), p.670-672

2012

Link zum Volltext

Verfügbarkeit prüfen

Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis

Cell stem cell, 2017-10, Vol.21 (4), p.489-501.e7

2017

Link zum Volltext

Verfügbarkeit prüfen

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Cancer cell, 2015-07, Vol.28 (1), p.15-28

2015

Link zum Volltext

Verfügbarkeit prüfen

Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell–stimulated T cells yet preserves immunity to recall antigen

Blood, 2011-11, Vol.118 (19), p.5330-5339

2011

Link zum Volltext

Verfügbarkeit prüfen

AKT is a therapeutic target in myeloproliferative neoplasms

Leukemia, 2013-09, Vol.27 (9), p.1882-1890

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 494: Evaluation of soluble FLT3 ligand as a marker of bone marrow stress and recovery

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.494-494

2016

Link zum Volltext

Verfügbarkeit prüfen

Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant

Blood, 2019-11, Vol.134 (Supplement_1), p.5186-5186

2019

Link zum Volltext

Verfügbarkeit prüfen

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms

Haematologica (Roma), 2020-03, Vol.105 (3), p.e91-e94

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1516: Deep profiling of T-cell repertoire and tumor heterogeneity in chronic lymphocytic leukemia patients following allogeneic T-cell therapy

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1516-1516

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2559: Generation and evaluation of an FLT3 CAR-T cell therapy for the treatment of acute myeloid leukemia

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2559-2559

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract IA41: Role of JAK-STAT pathway activation in MPN pathogenesis and therapeutic response

Clinical cancer research, 2015-09, Vol.21 (17_Supplement), p.IA41-IA41

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(54)
Buchkapitel
(1)

Sprache

Englisch
(55)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(28)
Life Sciences & Biomedicine
(27)
Humans
(21)
Animals
(17)
Mice
(12)
Oncology
(12)
Janus Kinase 2 - Antagonists & Inhibitors
(10)
Janus Kinase 2 - Genetics
(10)
Female
(9)
Hematology
(8)
Myeloproliferative Disorders - Drug Therapy
(8)
Signal Transduction - Drug Effects
(8)
Biological And Medical Sciences
(7)
Cell Biology
(7)
Medical Sciences
(7)
Mutation
(7)
Protein Kinase Inhibitors - Pharmacology
(7)
Cell Line, Tumor
(6)
Janus Kinase 2 - Metabolism
(6)
Male
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Heterodimeric JAK―STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition

JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent

Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma

Constitutive Activation of Signal Transducer and Activator of Transcription 5 Contributes to Tumor Growth, Epithelial-Mesenchymal Transition, and Resistance to Epidermal Growth Factor Receptor Targeting

Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1

Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms

STATe-of-the-art approach: using oligonucleotide decoys to target the "undruggable"

Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell–stimulated T cells yet preserves immunity to recall antigen

AKT is a therapeutic target in myeloproliferative neoplasms

Abstract 494: Evaluation of soluble FLT3 ligand as a marker of bone marrow stress and recovery

Characterization of Changes in the T-Cell Receptor Repertoire in Patients with Acute Myeloid Leukemia with Durable Remission Following Allogeneic Stem Cell Transplant

Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms

Abstract 1516: Deep profiling of T-cell repertoire and tumor heterogeneity in chronic lymphocytic leukemia patients following allogeneic T-cell therapy

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Abstract 2559: Generation and evaluation of an FLT3 CAR-T cell therapy for the treatment of acute myeloid leukemia

Abstract IA41: Role of JAK-STAT pathway activation in MPN pathogenesis and therapeutic response

Suchergebnisse filtern